logo
Share SHARE
FONT-SIZE Plus   Neg

Encana, Mitsubishi Partner To Develop Cutbank Ridge Undeveloped Lands

Encana Corp. (ECA,ECA.TO) reached an agreement with Mitsubishi Corp. that would see the Japanese global integrated business enterprise invest nearly C$2.9 billion for a 40 percent interest in the Cutbank Ridge Partnership. The Partnership holds about 409,000 net acres of Encana's undeveloped Montney-formation natural gas lands in the company's Cutbank Ridge resource play in northeast British Columbia. As part of the Cutbank Ridge Partnership, Encana and Mitsubishi intend to create long-term shareholder value by jointly developing production capacity to deliver abundant natural gas to markets for decades ahead.

Pursuant to the deal, Encana would own 60 percent and Mitsubishi would own 40 percent of the Cutbank Ridge Partnership. Mitsubishi would pay C$1.45 billion on closing, which may occur later this month, and Mitsubishi would invest C$1.45 billion in addition to its 40 percent of the Partnership's future capital investment for a commitment period, which is expected to be about five years, thereby reducing Encana's capital funding commitments to 30 percent of the total expected capital investment over that period.

Randy Eresman, Encana's President & Chief Executive, said, Despite an increased capital spending profile on these natural gas assets resulting from this transaction, Encana plans to more than offset the near term impact on North American natural gas production oversupply by capital spending reductions elsewhere in its natural gas portfolio."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT